Published in final edited form as:

Org Lett. 2009 July 16; 11(14): 3108–3111. doi:10.1021/ol901096d.

Concise Synthesis of the Bryostatin A-Ring *via* Consecutive C-C Bond Forming Transfer Hydrogenations

Yu Lu and Michael J. Krische*

University of Texas at Austin, Department of Chemistry and Biochemistry, Austin, TX 78712

Abstract

8 Steps Using 2 Different C-C Bond Forming Hydrogenations
The Same A-Ring was Previously Made in 17 Steps

Under the conditions of C-C bond forming transfer hydrogenation, 1,3-propanediol 1 engages in double asymmetric carbonyl allylation to furnish the C_2 -symmetric diol 2. Double ozonolysis of 2 followed by TBS protection delivers aldehyde 3, which is subject to catalyst directed carbonyl prenylation via transfer hydrogenation to deliver neopentyl alcohol 4 and, ultimately, the bryostatin A-ring 7. Through use of two consecutive C-C bond forming transfer hydrogenations, the Evans' bryostatin A-ring 7 is prepared in less than half the manipulations previously reported.

Originally isolated from the bryozoan *Bugula neritina*,¹ the bryostatins are a family of over 20 marine natural products that possess a polyacetate backbone and differ largely on the basis of substitution at C_7 and C_{21} (Figure 1, Top).² The bryostatins exhibit a remarkable range of biological effects, including antineoplastic activity against diverse tumor cell lines, immunopotentiating activity, restoration of apoptotic function, and the ability to act synergistically with other chemotherapeutic agents.³ More recently, the bryostatins have been found to exhibit exciting neurological effects, including activity against Alzheimer's disease,⁴ neural growth and repair and the reversal of stroke damage,⁵ as well as memory enhancement.⁶

The natural abundance of bryostatins is woefully insufficient to advance clinical studies and elucidate their precise mechanism of action.⁷ Consequently, the *de novo* synthesis of various bryostatins and the design and preparation of non-natural functional analogues has been the topic of intensive investigation. To date, total syntheses of bryostatin 2, bryostatin 3, bryostatin 7 and bryostatin 16 have been reported by Evans,⁸ Yamamura,⁹ Masamune,¹⁰ and Trost,¹¹

mkrische@mail.utexas.edu.

Supporting Information Available. Spectral data for all new compounds (^1H NMR, ^{13}C NMR, IR, HRMS). This material is available free of charge *via* the internet at <http://pubs.acs.org>.

respectively. A formal synthesis of bryostatin 7 was reported by Hale.¹² Finally, several creative synthetic approaches to bryostatin fragments are reported by Hale,¹³ Thomas,¹⁴ Hoffman,¹⁵ Vandewalle,¹⁶ Burke,¹⁷ and the present author.¹⁸ Although impressive, these syntheses do not represent a practical source of material for clinical study. Hence, efforts led by Wender,^{19,20} Keck²¹ and Hale^{13b} have focused on the design of simplified structural analogues that possess enhanced functional capability and provide insight into key structural features of the bryostatins that confer unique biological activity (Figure 1, bottom).

As part of a broad program aimed at the development of hydrogen-mediated C-C bond formations,²² enantioselective carbonyl allylations,^{23 a-c} crotylations^{23d} and reverse prenylations^{23e} recently were achieved under the conditions of iridium catalyzed transfer hydrogenation. A long term goal of these studies resides in defining a departure from preformed organometallic reagents in carbonyl and imine addition, thereby circumventing the excessive pre-activation and waste generation associated with their use. Furthermore, the ability to achieve asymmetric carbonyl addition directly from the alcohol oxidation level, as established by the aforementioned processes, is inherently more redox-economic and, hence, step-economic than classical protocols. Given the longstanding challenges associated with defining concise routes to the bryostatins, this class of natural products was deemed an ideal vehicle to benchmark the utility of C-C bond forming hydrogenations and transfer hydrogenations developed in our laboratory. In prior work, enantioselective hydrogen-mediated alkyne-carbonyl reductive coupling was applied to construction of the bryostatin C-ring. Here, using two different C-C bond forming transfer hydrogenations, we disclose a synthetic route to a known bryostatin A-ring fragment in less than half the steps previously required.⁸

Our initial step toward the bryostatin A-ring employs the double asymmetric carbonyl allylation of 1,3-propanediol **1** to furnish the *C*₂-symmetric diol **2**,^{23c} which is obtained in > 99% ee as the minor enantiomer of the mono-adduct is converted to the *meso*-isomer of the *bis*-adduct.²⁴ Identical material was previously prepared in four steps from acetylacetone.²⁵ Notably, this particular carbonyl allylation cannot be achieved directly from the aldehyde oxidation level due to the instability of malondialdehyde. The *C*₂-symmetric diol **2** was subjected to double ozonolysis followed by protection *in situ* as the *bis*-TBS ether to deliver aldehyde **3**. Because the transient dialdehyde moieties that arise upon ozonolysis are homotopic, pyran **3** appears as a single isomer (Scheme 1).

The stage was now set for catalyst-directed prenylation of aldehyde **3** under previously disclosed transfer hydrogenation conditions.^{23e} Upon exposure of aldehyde **3** to 1,1-dimethylallene and isopropanol in the presence of the iridium *C,O*-benzoate generated *in situ* from allyl acetate, *m*-nitrobenzoic acid and (*R*)-SEGPPOS,²⁶ a 92% isolated yield of the prenylated adduct **4** was obtained as a 1:11 (*S*:*R*) ratio of epimers at 60 °C. Using the catalyst derived from (*S*)-SEGPPOS under otherwise identical conditions, the prenylated adduct **4** was obtained as a 16:1 (*S*:*R*) ratio of epimers. These data suggest that the catalysts derived from (*R*)- and (*S*)-SEGPPOS are mismatched and matched, respectively, with regard to the inherent diastereofacial bias of aldehyde **3**. Indeed, upon use of the corresponding achiral iridium complex derived from BIPHEP, the prenylated adduct **4** was obtained as a 1.4:1 (*S*:*R*) ratio of epimers corroborating a fortuitous bias of the substrate toward formation of the (*S*)-epimer. By isolating the catalyst derived from (*S*)-SEGPPOS and employing it at slightly lower temperature (50 °C), the prenylated adduct **4** was obtained in 90% isolated yield as a single (*S*)-epimer as determined by ¹H NMR (Scheme 2).

Transformation of the neopentyl alcohol **4** to the bryostatin A-ring was accomplished in five manipulations. In accordance with literature precedent,²⁷ the neopentyl alcohol **4** was converted to the corresponding *p*-methoxybenzyl ether in 78% isolated yield. Selective removal of the lactol TBS ether was achieved using TBAF-AcOH, also in 78% isolated yield.

²⁸ Finally, Jones oxidation of the lactol delivers lactone **5** in 81% isolated yield.²⁹ Ring opening of lactone **5** mediated by AlMe₃-PhNH₂ provides anilide **6** in 84% isolated yield,⁸ which upon ozonolysis furnishes the previously reported bryostatin A-ring fragment **7**⁸ in a total of eight manipulations from 1,3-propanediol **1** (Scheme 1).³⁰ Notably, this material was prepared previously in 12 steps from 2,2-dimethyl-4,4-diphenyl-3-butenal, which itself is prepared in five steps from 3-chloro-2-methylpropene,³¹ thus representing a total of 17 steps from 3-chloro-2-methylpropene.

To summarize, it is well-appreciated that new synthetic methods beget new synthetic strategies that can dramatically simplify the preparation of target substances. Here, through consecutive use of C-C bond forming transfer hydrogenations, a remarkably concise synthesis of a known bryostatin A-ring fragment was achieved in less than half the manipulations previously required. In earlier work utilizing hydrogen-mediated alkyne-carbonyl reductive coupling, a route to the bryostatin C-ring was established.¹⁸ Future studies will focus on total syntheses of the bryostatins and simplified structural analogues that possess enhanced functional capability, taking advantage of the simplifications availed through C-C bond forming hydrogenation and transfer hydrogenation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Acknowledgment is made to the Robert A. Welch Foundation and the NIH-NIGMS (RO1-GM069445) for partial support of this research. Dr. Oliver Briel of Umicore is thanked for the generous donation of [Ir(cod)Cl]₂. Takasago is thanked for the generous donation of (S)-SEGPLHOS.

References

1. Pettit GR, Herald CL, Doubek DL, Herald DL, Arnold E, Clardy J. *J Am Chem Soc* 1982;104:6846.
2. (a) Pettit GR. *J Nat Prod* 1996;59:812. [PubMed: 8792630] (b) Lopanik N, Gustafson KR, Lindquist N. *J Nat Prod* 2004;67:1412. [PubMed: 15332866]
3. For selected reviews encompassing the biological properties of the bryostatins, see: (a) Hale KJ, Hummersone MG, Manaviar S, Frigerio M. *Nat Prod Rep* 2002;19:413. [PubMed: 12195811] (b) Kortmanský J, Schwartz GK. *Cancer Invest* 2003;21:924. [PubMed: 14735696] (c) Wender PA, Baryza JL, Hilinski MK, Horan JC, Kan C, Verma VA, Huang Z. *Beyond Natural Products: Synthetic Analogues of Bryostatin 1*. In *Drug Discovery Research: New Frontiers in the Post-Genomic Era* Wiley-VCH Hoboken, NJ 2007:127–162. 162
4. (a) Etcheberrigaray R, Tan M, Dewachter I, Kuiperi C, Van der Auwera I, Wera S, Qiao L, Bank B, Nelson TJ, Kozikowski AP, Van Leuven F, Alkon DL. *Proc Natl Acad Sci USA* 2004;101:11141. [PubMed: 15263077] (b) Alkon DL, Sun MK, Nelson TJ. *Trends Pharmacol Sci* 2007;28:51. [PubMed: 17218018]
5. Sun MK, Hongpaisan J, Nelson TJ, Alkon DL. *Proc Natl Acad Sci USA* 2008;105:13620. [PubMed: 18768786]
6. (a) Alkon DL, Epstein H, Kuzirian A, Bennett MC, Nelson TJ. *Proc Natl Acad Sci USA* 2005;102:16432. [PubMed: 16258064] (b) Sun MK, Alkon DL. *Eur J Pharmacol* 2005;512:43. [PubMed: 15814089]
7. Schaufelberger DE, Koleck MP, Beutler JA, Vatakis AM, Alvarado AB, Andrews P, Marzo LV, Muschik GM, Roach J, Ross JT, Lebherz WB, Reeves MP, Eberwein RM, Rodgers LL, Testerman RP, Snader KM, Forenza S. *J Nat Prod* 1991;54:1265. [PubMed: 1800630]
8. (a) Evans DA, Carter PH, Carreira EM, Prunet JA, Charette AB, Lautens M. *Angew Chem Int Ed* 1998;37:2354. (b) Evans DA, Carter PH, Carreira EM, Charette AB, Prunet JA, Lautens M. *J Am Chem Soc* 1999;121:7540.

9. (a) Ohmori K, Ogawa Y, Obitsu T, Ishikawa Y, Nishiyama S, Yamamura S. *Angew Chem Int Ed* 2000;39:2290. (b) Ohmori K. *Bull Chem Soc Jpn* 2004;77:875.
10. Kageyama M, Tamura T, Nantz M, Roberts JC, Somfai P, Whrittenour DC, Masamune S. *J Am Chem Soc* 1990;112:7407.
11. Trost BM, Dong G. *Nature* 2008;456:485. [PubMed: 19037312]
12. Manaviazar S, Frigerio M, Bhatia GS, Hummersone MG, Aliev AE, Hale KJ. *Org Lett* 2006;8:4477. [PubMed: 16986929]
13. (a) Review: Hale KJ, Hummersone MG, Cai J, Manavaiazar S, Bhatia GS, Lennon JA, Frigerio M, Delisser VM, Chumnongsaksarp A, Jogiya N, Lemaitre A. *Pure Appl Chem* 2000;72:1659.(b)Hale KJ, Frigerio M, Manaviazar S, Hummersone MG, Fillingham IJ, Barsukov IG, Damblon CF, Gescher A, Roberts GCK. *Org Lett* 2003;5:499. [PubMed: 12583753](c)Hale KJ, Frigerio M, Manaviazar S. *Org Lett* 2003;5:503. [PubMed: 12583754](d)Hale KJ, Frigerio M, Manaviazar S. *Org Lett* 2001;3:3791. [PubMed: 11700140](e)Hale KJ, Lennon JA, Manaviazar S, Javaid MH, Hobbs CJ. *Tetrahedron Lett* 1995;36:1359.(f)Hale KJ, Hummersone MG, Bhatia GS. *Org Lett* 2000;2:2189. [PubMed: 10930240]
14. (a) Review: Baron A, Ball M, Bradshaw B, Donnelly S, Gerday O, Oller PC, Kumar N, Martin N, O'Brien M, Omori H, Moore C, Thomas EJ. *Pure Appl Chem* 2005;77:103.(b)Green AP, Hardy S, Thomas EJ. *Synlett* 2008:2103.
15. (a) Lampe TFJ, Hoffman HMR. *Chem Commun* 1996:1931. (b) Lampe TFJ, Hoffman HMR. *Tetrahedron Lett* 1996;37:7695. (c) Weiss J, Hoffman HMR. *Tetrahedron: Asymmetry* 1997;8:3913. (d) Vakalopoulos A, Lampe TFJ, Hoffman HMR. *Org Lett* 2001;3:929. [PubMed: 11263918] (e) Seidel MC, Smits R, Stark CBW, Frackenpohl J, Gaertzen O, Hoffman HMR. *Synthesis* 2004:1391.
16. (a) De Brabander J, Vanhessche K, Vandewalle M. *Tetrahedron Lett* 1991;32:2821. (b) De Brabander J, Vandewalle M. *Synlett* 1994:231. (c) De Brabander J, Vandewalle M. *Synthesis* 1994:855. (d) De Brabander J, Kulkarni A, Garcia-Lopez R, Vandewalle M. *Tetrahedron: Asymmetry* 1997;8:1721.
17. (a) Voight EA, Seradj H, Roethle PA, Burke SD. *Org Lett* 2004;6:4045. [PubMed: 15496095] (b) Voight EA, Roethle PA, Burke SD. *J Org Chem* 2004;69:4534. [PubMed: 15202915]
18. Cho CW, Krische MJ. *Org Lett* 2006;8:891. [PubMed: 16494467]
19. For recent contributions to the primary literature, see: (a)Wender PA, Verma VA. *Org Lett* 2006;8:1893. [PubMed: 16623578](b)Wender PA, Horan JC. *Org Lett* 2006;8:4581. [PubMed: 16986955](c)Wender PA, Horan JC, Verma VA. *Org Lett* 2006;8:5299. [PubMed: 17078702](d) Wender PA, Verma VA. *Org Lett* 2008;10:3331. [PubMed: 18588309](e)Wender PA, DeChristopher BA, Schreier AJ. *J Am Chem Soc* 2008;130:6658. [PubMed: 18452292]
20. Reviews: (a)Wender PA, Martin-Cantalejo Y, Carpenter AJ, Chiu A, De Brabander J, Harran PG, Jimenez JM, Koehler MFT, Lippa B, Morrison JA, Müller SG, Müller SN, Park CM, Shiozaki M, Siedenbiedel C, Skaltsky DJ, Tanaka M, Irie K. *Pure Appl Chem* 1998;70:539.(b)Wender PA, Hinkle KW, Koehler MFT, Lippa B. *Med Res Rev* 1999;19:388. [PubMed: 10502742](c)Wender PA, Baryza JL, Brenner SE, Clarke MO, Gamber GG, Horan JC, Jessop TC, Kan C, Pattabiraman K, Williams TJ. *Pure Appl Chem* 2003;75:143.(d) And reference 3c.
21. (a) Keck GE, Truong AP. *Org Lett* 2005;7:2153. [PubMed: 15901157] (b) Keck GE, Welch DS, Vivian PK. *Org Lett* 2006;8:3667. [PubMed: 16898787] (c) Keck GE, Welch DS, Poudel YB. *Tetrahedron Lett* 2006;47:8267. [PubMed: 17404602] (d) Keck GE, Kraft MB, Truong AP, Li W, Sanchez CC, Kedei N, Lewin NE, Blumberg PM. *J Am Chem Soc* 2008;130:6660. [PubMed: 18452293] (e) Keck GE, Poudel YB, Welch DS, Kraft MB, Truong AP, Stephens JC, Kedei N, Lewin NE, Blumberg PM. *Org Lett* 2009;11:593. [PubMed: 19113896]
22. For selected reviews on C-C bond forming hydrogenation and transfer hydrogenation, see: (a)Ngai MY, Kong JR, Krische MJ. *J Org Chem* 2007;72:1063. [PubMed: 17288361](b)Skucas E, Ngai MY, Komanduri V, Krische MJ. *Acc Chem Res* 2007;40:1394. [PubMed: 17784728](c)Shibahara F, Krische MJ. *Chem Lett* 2008;37:1102.(d)Bower JF, Kim IS, Patman RL, Krische MJ. *Angew Chem Int Ed* 2009;48:34.
23. (a) Kim IS, Ngai MY, Krische MJ. *J Am Chem Soc* 2008;130:6340. [PubMed: 18444616] (b) Kim IS, Ngai MY, Krische MJ. *J Am Chem Soc* 2008;130:14891. [PubMed: 18841896] (c) Lu Y, Kim IS, Hassan A, Del Valle DJ, Krische MJ. *Angew Chem Int Ed* 2009;48In Press (d) Kim IS, Han SB, Krische MJ. *J Am Chem Soc* 2009;131:2514. [PubMed: 19191498] (e) Han SB, Kim IS, Han H, Krische MJ. *J Am Chem Soc* 2009;131:6916. [PubMed: 19453190]

24. This mechanism for enantiomeric enrichment is documented by Eliel and Midland: (a) Kogure T, Eliel ELJ. *Org Chem* 1984;49:576. (b) Midland MM, Gabriel J. *J Org Chem* 1985;50:1144.
25. Rychnovsky SD, Griesgraber G, Powers JP. *Org Synth* 2000;77:1.
26. SEGPHOS: Saito T, Yokozawa T, Ishizaki T, Moroi T, Sayo N, Miura T, Kumobayashi H. *Adv Synth Catal* 2001;343:264.
27. Wipf P, Graham TH. *J Am Chem Soc* 2004;126:15346. [PubMed: 15563138]
28. Orgueira HA, Bartolozzi A, Schell P, Litjens RE, Palmacci ER, Seeberger PH. *Chem Eur J* 2003;9:140.
29. Hung DT, Nerenberg JB, Schreiber SL. *J Am Chem Soc* 1996;118:11054.
30. With regard to the assignment of relative and absolute stereochemistry, the optical rotation of C_2 -symmetric diol 2 was correlated with reported data (see reference 25 and supporting information). In the reverse prenylation of 3, the undesired diastereomer of adduct 4 obtained using (*R*)-SEGPHOS as ligand was used to complete the A-ring. As anticipated, the ^1H NMR data did not match the reported data. In contrast, the A-ring diastereomer obtained using (*S*)-SEGPHOS as ligand in the prenylation step matches the reported data, notwithstanding a small difference in the ratio of diastereomers at C9.
31. (a) Julia M, Baillarge M. *Bull Soc Chim Fr* 1966:734. (b) Zimmerman HE, Pratt AC. *J Am Chem Soc* 1970;92:6259.

Figure 1.

Top: Structures of bryostatins 1–17. Bottom: Selected bryostatin analogues and binding affinities for PKC α .

Scheme 1.

Synthesis of the bryostatin A-ring employing consecutive C-C bond forming transfer hydrogenations.

(*R*)-SEGPHOS-Ir-Complex I: **4**, 92% Yield, 1:11 dr (*S*:*R*) @ 60 °C
 (*S*)-SEGPHOS-Ir-Complex I: **4**, 90% Yield, 16:1 dr (*S*:*R*) @ 60 °C
 BIPHEP-Ir-Complex I: **4**, 87% Yield, 1.4:1 dr (*S*:*R*) @ 60 °C
 (*S*)-SEGPHOS-Ir-Complex I: **4**, 90% Yield, $\geq 20:1$ dr (*S*:*R*) @ 50 °C ← Isolated Catalyst

} *In Situ* Catalyst Generation

Scheme 2.

Catalyst directed diastereoselectivity in the transfer hydrogenative reverse prenylation of aldehyde **3**.